Reduced cancer incidence in Huntington's disease: Record linkage study clue to an evolutionary trade-off?

Clinical Genetics

Volumn 83, Issue 6, 2013, Pages 588-590

  Turner, M R ^a   Goldacre, R ^a   Goldacre, M J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HUNTINGTIN; POLYGLUTAMINE;

APOPTOSIS; CAG REPEAT; CANCER INCIDENCE; CANCER PREVENTION; DISEASE ASSOCIATION; HEREDITARY ATAXIA; HOSPITAL ADMISSION; HUMAN; HUNTINGTON CHOREA; KENNEDY DISEASE; LETTER; MEDICAL RECORD; PRIORITY JOURNAL; PROTEIN EXPRESSION;

COHORT STUDIES; COMORBIDITY; ENGLAND; HUMANS; HUNTINGTON DISEASE; INCIDENCE; INTERNATIONAL CLASSIFICATION OF DISEASES; NEOPLASMS; PEPTIDES; TRINUCLEOTIDE REPEAT EXPANSION;

EID: 84876812693     PISSN: 00099163     EISSN: 13990004     Source Type: Journal    
DOI: 10.1111/cge.12010     Document Type: Letter

References (5)

1. Sorensen SA, Fenger K, Olsen JH. Significantly lower incidence of cancer among patients with Huntington disease: an apoptotic effect of an expanded polyglutamine tract? Cancer 1999: 86: 1342-1346.
2. Ji J, Sundquist K, Sundquist J. Cancer incidence in patients with polyglutamine diseases: a population-based study in Sweden. Lancet Oncol 2012: 13: 642-648.
3. Fois AF, Wotton CJ, Yeates D, Turner MR, Goldacre MJ. Cancer in patients with motor neuron disease, multiple sclerosis and Parkinson's disease: record linkage studies. J Neurol Neurosurg Psychiatry 2010: 81: 215-221.
4. Ehret JC, Day PS, Wiegand R, Wojcieszek J, Chambers RA. Huntington disease as a dual diagnosis disorder: data from the National Research Roster for Huntington disease patients and families. Drug Alcohol Depend 2007: 86: 283-286.
5. Andrew SE, Hayden MR. Origins and evolution of Huntington disease chromosomes. Neurodegeneration 1995: 4: 239-244.